AKTS — Aktis Oncology, Inc. Common stock

Stock analysis, AI verdict, fundamentals & technical signals

Rating: NEUTRAL

Price: $15.93 Analyst target: $35.88 Upside: 125.24%

About Aktis Oncology, Inc. Common stock

Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures and sells radio frequency (RF) filter products for the wireless mobile device industry in the United States. The company is headquartered in Huntersville, North Carolina.

See the full interactive analysis & chart →

Informational only — not investment advice.